‘Michael’ Electrifies the Box Office: 5 Reasons Bad Reviews Couldn’t Derail the Michael Jackson Biopic

"Michael" delivered a blockbuster first weekend with $97 million domestically and $217 million globally, setting the record for the biggest opening ever for a musical biopic and becoming Lionsgate’s largest hit since 2015. The film’s strong A- CinemaScore, IMAX contribution of $13.8 million domestically, and broad audience appeal suggest durable box office momentum despite weak reviews and prior legal/budget complications. The success materially improves Lionsgate’s theatrical outlook and increases the odds of a sequel.

Analysis

The market is underestimating how much of this is an exhibition-quality signal rather than a one-off content win. A breakout music event with strong word-of-mouth shifts the negotiating leverage toward formats that monetize the big-screen premium—IMAX, PLF screens, premium seating, and concession mix—because these titles create a higher willingness-to-pay and extend dwell time. That matters most for operators and format licensors over the next 1-2 quarters, not just for the studio at opening weekend.

IMAX is the cleanest second-order beneficiary because the film validated the thesis that concert-like, nostalgia-heavy product can outperform on premium large format share even when critical reception is mixed. The incremental economics are attractive: a high-teen share of domestic box office from a single title suggests that if the next wave of music/event films holds up, IMAX can sustain outsized per-screen revenue without requiring a broad box office rebound. The risk is that this becomes a one-title halo trade; if subsequent event films fail to replicate the communal-experience effect, the multiple expansion should compress quickly.

The bigger contrarian read is that the sequel/setup ending creates both upside and a valuation trap. A follow-on chapter that moves deeper into controversy may not have the same four-quadrant appeal, so the franchise may be front-loading demand from the least problematic portion of the story. That means the current enthusiasm likely over-discounts medium-term franchise durability while under-discounting legal, reputational, and creative overhangs for any future installment.

For Lionsgate, this is a sentiment reset, but not yet a structural rerating. The studio still needs to prove that the recent run is a repeatable commissioning edge rather than timing luck plus event-format tailwinds. If upcoming releases maintain the same “best experienced together” profile, the market can start assigning a higher probability to sustained margin recovery; if not, this quarter’s success will look episodic rather than secular.

Key Decisions for Investors

• Long IMAX into the next 4-8 weeks on the thesis that premium-format share stays elevated through the next event release cycle; target 10-15% upside versus a tight 6-8% stop if subsequent openings disappoint.
• Pair trade: long IMAX / short a broad theater operator basket over 1-2 quarters. The alpha comes from format monetization, while the short leg is exposed to flat attendance and fixed-cost leverage if the broader slate softens.
• Buy January 2026 IMAX calls on pullbacks, using 20-30 delta strikes to express upside from a multi-title event-film pipeline. Risk/reward is favorable if premium-screen utilization remains above trend for two reporting periods.
• Avoid chasing Lionsgate equity purely on this print; if long, treat as a tactical trade only and fade strength into the next release slate. The current setup has more headline optionality than durable earnings visibility.
• Watch for follow-on announcements on additional music biopics or premium-format commitments; if two more titles are greenlit within 60-90 days, re-rate IMAX higher and add to position.